#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Czecho-Slovak Pathology / 2025 - 4

Predictive factors assessment in breast cancer treatment

Czech version

Authors: Magdalena Hudcová;  Bohuslav Melichar
Authors‘ workplace: Onkologická klinika, Univerzita Palackého Olomouc a Fakultní nemocnice Olomouc, Česká republika
Published in: Čes.-slov. Patol., 61, 2025, No. 4, p. 195-200
Category: Reviews Article

Overview

Breast cancer is the most common type of solid tumors in women. Breast cancer treatment at each stage of the disease is based on results describing genetic changes present in the tumor cells. Since breast cancer is not a homogeneous disease, its treatment approaches differ with respect to individual subgroups of breast cancer defined at the basic level by the expression of hormone receptors, HER2 receptor and Ki-67 marker. More recently described genetic changes in breast cancer cells significantly expand the treatment options, but on the other hand mean new challenges and demands in the further investigation of tumor samples. The following is a brief overview of prognostic and predictive markers used in breast cancer. The evaluation of these markers is in the hands of pathologists.

Keywords:

predictive factors – breast cancer – treatment – hormonal receptors – HER2 – triple negative

Sources
  1. ÚZIS ČR. Novotvary 2019–2021 ČR [online]. Praha: ÚZIS ČR; 202x [cit. 2025-04-25]. Dostupné z: https://www.uzis.cz/index.php?p- g=aktuality&aid=8646.
  2. Freelander A, Brown LJ, Parker A et al. Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. Genes (Basel) 2021; 12(2): 285.
  3. Lamb CA, Vanzulli SI et Lanari C. Hormone receptors in breast cancer: more than estrogen receptors. Medicina (B Aires) 2019; 79(Spec 6/1): 540-545.
  4. Ronchi A, Pagliuca F, Zito Marino F et al. Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma. Semin Cancer Biol 2021 : 114-122.
  5. Cheang MCU, Chia SK, Voduc D et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. J Natl Cancer Inst 2009; 101(10): 736-750.
  6. Rakha EA, Reis-Filho JS et Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010; 120(2): 293-308.
  7. Rakha EA, Chmielik E, Schmitt FC et al. Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates. Pathobiology 2022; 89(5): 263-277.
  8. Allison KH, Hammond MEH, Dowsett M et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 2020; 144(5): 545-563.
  9. Qureshi Z, Jamil A, Altaf F et al. Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review. Ann Med Surg (Lond) 2024; 86(8): 4624-4633.
  10. Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract 2007; 61(12): 2051-2063.
  11. Harbeck N, Rastogi P, Martin M et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32(12): 1571-1581.
  12. Hortobagyi GN, Lacko A, Sohn J et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol 2025; 36(2): 149-157.
  13. Hortobagyi GN, Stemmer SM, Burris HA et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375(18): 1738-1748.
  14. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351(27): 2817-2826.
  15. Sparano JA, Gray RJ, Makower DF et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018; 379(2): 111-121.
  16. Kalinsky K, Barlow WE, Gralow JR et al. 21Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med 2021; 385(25): 2336-2347.
  17. Cardoso F, Van‘t Veer L, Rutgers E et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26(5): 729-735.
  18. Cardoso F, Van‘t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375(8): 717-729.
  19. Johnston S, Martin M, Di Leo A et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 2019 : 5: 5.
  20. Finn RS, Martin M, Rugo HS et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375(20): 1925-1936.
  21. Toy W, Weir H, Razavi P et al. Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discov 2017; 7(3): 277-287.
  22. Chandarlapaty S, Chen D, He W et al. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol 2016; 2(10): 1310-1315.
  23. Bardia A, Cortés J, Bidard FC et al. Elacestrant in ER+, HER2Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clin Cancer Res 2024; 30(19): 4299-4309.
  24. Cizkova M, Susini A, Vacher S et al. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res 2012; 14(1): R28.
  25. Cizkova M, Vacher S, Meseure D et al. PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer 2013 : 13 : 545.
  26. André F, Ciruelos E, Rubovszky G et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380(20): 1929-1940.
  27. André F, Ciruelos EM, Juric D et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021; 32(2): 208-217.
  28. Turner NC, Oliveira M, Howell SJ et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2023; 388(22): 2058-2070.
  29. Zardavas D, Irrthum A, Swanton C et la. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 2015; 12(7): 381-394.
  30. Rubin I et Yarden Y. The basic biology of HER2. Ann Oncol 2001 : 12 Suppl 1: S3-8.
  31. Nitta H, Kelly BD, Allred C et al. The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int 2016; 66(6): 313-324.
  32. Martínez-Sáez O et Prat A. Current and Future Management of HER2-Positive Metastatic Breast Cancer. JCO Oncol Pract 2021; 17(10): 594-604.
  33. Ziegengeist JL et Tan AR. A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer. Clin Breast Cancer 2025; 25(2): e124-e132.
  34. Xia X, Gong C, Zhang Y et al. The History and Development of HER2 Inhibitors. Pharmaceuticals (Basel) 2023; 16(10): 1450.
  35. Modi S, Jacot W, Yamashita T et al. Trastuzumab Deruxtecan in Previously Treated HER-2-Low Advanced Breast Cancer. N Engl J Med 2022; 387(1): 9-20.
  36. Davey MG, Hynes SO, Kerin MJ et al. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel) 2021; 13(17): 4455.
  37. Royce M, Mulkey F, Osgood C et al. US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer. J Clin Oncol 2023; 41(18): 3456-3457.
  38. Schmid P, Cortes J, Dent R et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 2024; 391(21): 1981-1991.
  39. Antonini M, Mattar A, Melo Pereira T et al. Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: A systematic review and meta-analysis of real-world data. J heliyon 2025; e43069.
  40. Quintanar-Verdúguez MT, Ballester Espinosa M, Pérez-Altozano J et al. How can we integrate current adjuvant treatment options in triple negative patients with residual disease after neoadjuvant treatment? Revista de Senología y Patología Mamaria 2025; 38 : 100633.
  41. Schmid P, Adams S, Rugo HS et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379(22): 2108-2121.
  42. Cortes J, Cescon DW, Rugo HS et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396(10265): 1817-1828.
  43. Le DT, Uram JN, Wang H et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372(26): 2509-2520.
  44. Le DT, Durham JN, Smith KN et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357(6349): 409-413.
  45. Wen YH, Brogi E, Zeng Z et al. DNA Mismatch Repair Deficiency in Breast Carcinoma. A Pilot Study of Triple-negative and Non–Triple-negative Tumors. Am J Surg Pathol 2012; 36(11): 1700-1708.
  46. Novotný J, Cibula D, Curtisová V et al. Doporučené postupy klinické péče o nosiče zárodečných mutací v genech MLH1, MSH2, MSH6, PMS2 a velkých delecí EPCAM predisponujících ke vzniku Lynchova syndromu. Klin Onkol 2024; 37(5): 384-389.
  47. Chalmers ZR, Connelly CF, Fabrizio D et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017; 9(1): 34.
  48. Yarchoan M, Hopkins A et Jaffee EM. 2017. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 2017; 377(25): 2500-2501.
  49. Tutt ANJ, Garber JE, Kaufman B et al. Adjuvant Olaparib for Patients with BRCA1or BRCA2-Mutated Breast Cancer. N Engl J Med 2021; 384(25): 2394-2405.
  50. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376(9737): 235-244.
  51. Litton JK, Rugo HS, Ettl J et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379(8): 753-763.
  52. Toss A, Ponzoni O, Riccò B et al. Management of PALB2-associated breast cancer: A literature review and case report. Clin Case Rep 2023; 11(8): e7747.
  53. O’Haire S, Franchini F, Kang YJ et al. Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours. Sci Rep 2023; 13(1): 4116.
  54. Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion –⁠ Positive Cancers in Adults and Children. N Engl J Med 2018; 378(8): 731-739.
  55. Hsiao SJ, Zehir A, Sireci AN et al. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. J Mol Diagn 2019; 21(4): 553-571.
Labels
Anatomical pathology Forensic medical examiner Toxicology
Editorial
Interview
Monitor
Papillary Breast Lesions: Diagnostic Challenges and Overview of Entities
Immunohistochemical assessment of HER2 protein in breast carcinomas – current status
Unusual histopathologic finding in axillary lymph node in patient with invasive breast carcinoma NST: Case report and literature review
An unusual case of late recurrent adult granulosa cell tumor and mature teratoma arising within the same ovary, confirmed by NGS analysis
Current methods in multiplex immunohistochemistry for formalin-fixed tissue samples
Article was published in

Czecho-Slovak Pathology

Issue 4
2025 Issue 4
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#